Holen Sie sich die Stockscreener-App
0.7212
0.52%
0.0037
Handel nachbörslich:
.70
-0.0212
-2.94%
Schlusskurs vom Vortag:
$0.7175
Offen:
$0.7078
24-Stunden-Volumen:
395.44K
Relative Volume:
2.12
Marktkapitalisierung:
$55.42M
Einnahmen:
$9.53M
Nettoeinkommen (Verlust:
$-44.61M
KGV:
-0.7925
EPS:
-0.91
Netto-Cashflow:
$-38.32M
1W Leistung:
-2.21%
1M Leistung:
-1.08%
6M Leistung:
-4.17%
1J Leistung:
-51.60%
1-Tages-Spanne:
$0.7078
$0.85
1-Wochen-Bereich:
$0.6801
$0.85
52-Wochen-Spanne:
$0.5406
$1.9891
Cue Biopharma Inc Stock (CUE) Company Profile
Firmenname
Cue Biopharma Inc
Sektor
Branche
Telefon
617-949-2680
Adresse
40 GUEST STREET, BOSTON, MA
Vergleichen Sie CUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.7212 | 55.14M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-13 | Eingeleitet | Jefferies | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-11-21 | Eingeleitet | Piper Sandler | Overweight |
| 2022-01-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-03 | Eingeleitet | Craig Hallum | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-04-09 | Eingeleitet | Stifel | Buy |
| 2020-01-28 | Eingeleitet | BTIG Research | Buy |
| 2020-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Cue Biopharma Inc Aktie (CUE) Neueste Nachrichten
How Cue Biopharma Inc. stock reacts to global recession fearsJuly 2025 Technicals & Real-Time Volume Analysis Alerts - newser.com
What is the fair value of Cue Biopharma Inc. stock now2025 Top Decliners & Entry Point Confirmation Alerts - newser.com
How Cue Biopharma Inc. stock performs in rate cut cycles2025 Volume Leaders & Growth Focused Entry Reports - newser.com
Is Cue Biopharma Inc. stock resilient to inflationQuarterly Profit Review & Long Hold Capital Preservation Plans - newser.com
Full technical analysis of Cue Biopharma Inc. stock2025 Analyst Calls & Weekly High Momentum Picks - newser.com
What dividend safety score for Cue Biopharma Inc. stockJuly 2025 Reactions & High Accuracy Trade Signal Alerts - newser.com
Cue Biopharma Inc. recovery potential after sell offJuly 2025 Breakouts & Capital Protection Trading Alerts - newser.com
Is Cue Biopharma Inc. stock in correction or buying zoneWeekly Profit Summary & Weekly Top Performers Watchlists - newser.com
Historical volatility pattern of Cue Biopharma Inc. visualized2025 Geopolitical Influence & Daily Stock Trend Watchlist - newser.com
Is Cue Biopharma Inc. stock gaining market shareIPO Watch & Risk Managed Investment Strategies - newser.com
Risk adjusted return profile for Cue Biopharma Inc. analyzedJuly 2025 Opening Moves & Free Weekly Chart Analysis and Trade Guides - newser.com
Can trapped investors hope for a rebound in Cue Biopharma Inc. - newser.com
Is Cue Biopharma Inc. reversing from oversold territoryJuly 2025 Highlights & Free Long-Term Investment Growth Plans - newser.com
Trend analysis for Cue Biopharma Inc. this weekJuly 2025 Summary & Scalable Portfolio Growth Methods - newser.com
Is Cue Biopharma Inc. stock vulnerable to regulatory risksDip Buying & Fast Momentum Stock Entry Tips - newser.com
How Cue Biopharma Inc. (1UC) stock stacks up against competitorsRate Hike & Free Community Supported Trade Ideas - newser.com
Live market analysis of Cue Biopharma Inc.2025 Year in Review & Fast Entry High Yield Stock Tips - newser.com
Using Ichimoku Cloud for Cue Biopharma Inc. technicalsJuly 2025 Big Picture & AI Optimized Trade Strategies - newser.com
Why Cue Biopharma Inc. (1UC) stock could be next leaderAnalyst Downgrade & Free Reliable Trade Execution Plans - newser.com
Short Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Declines By 44.6% - MarketBeat
Is Cue Biopharma Inc. (1UC) stock undervalued after correctionWeekly Market Outlook & Target Return Focused Stock Picks - newser.com
Finanzdaten der Cue Biopharma Inc-Aktie (CUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):